MedTrace Logo

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

NCT07142356 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2026-04-27

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the drug RT-001 works to reduce high blood pressure (hypertension) in adults. It will also learn about the safety of RTN-001. The main questions it aims to answer are:

Does RTN-001 lower blood pressure in patients who have uncontrolled hypertension? What medical problems do participants have when taking RTN-001?

Researchers will compare RTN-001 to a placebo (a look-alike substance that contains no drug) to see if RTN-001 works to treat uncontrolled hypertension.

Participants will:

Take RTN-001 or a placebo every day for 12 weeks Visit the clinic about once every 2 weeks for checkups and tests Keep a diary of their symptoms and all medications that they take including RTN-001

Conditions

Interventions

DRUG

RTN-001

A potent and selective PDE5 inhibitor.

DRUG

Matching placebo control

The reference/comparator product is a matching placebo tablet with similar appearance and weight as the RTN-001 oral tablet.

Sponsors & Collaborators

  • Retension Pharmaceuticals. Inc.

    lead INDUSTRY

Principal Investigators

  • William CMO, PhD · CMO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2026-10-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07142356 on ClinicalTrials.gov